2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational: Molecular and Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1747 Multiomic profiling of extranodal NK/T-cell lymphoma reveals convergent JAK–STAT and PD-L1 co-activation, HLA class I evasion via allele-specific expression loss, and therapeutic vulnerability to combination co-inhibition

Yoonhee Nam, Maria J. Fernandez-Turizo, MD2, Alexandra W Lenart, BS3, Khyati Kariya, PhD4, Sean McCabe5, Shauna Efstratios6, Makoto Iwasaki, MD, PhD7, Eric Minwei Liu, PhD8, Aliyah Sohani, MD9, Mark N Sorial, PharmD10, Mwanasha Merrill, MD11, Eric Jacobsen, MD12, Fabiola Valvert, MD13, Yu Ri Kim, MD14, So-Young Seol, MS15, Denisse Castro Jr, MD16, Brady Beltran, MD17, Sally Paredes, MD18, Pilar Quiñones, MD19, Veronica Leautaud, PhD20, Luis Malpica, MD21, Pierluigi Porcu, MD22, Xuejun Tian23, Pablo Ortiz-Romero, MD24, Carmen Maria Garcia, MD25, Maria Rodriguez Pinilla, MD26, Jia Ruan, MD, PhD27, Giorgio Inghirami, MD28, Maria Cabrera29, Pablo Villegas, MD30, Wonseog Kim, MD, PhD31, Jun Ho Jang32, Sang Eun Yoon33, Govind Bhagat, MD34, Craig R Soderquist, MD35, Carlos Sergio Chiattone Sr, MD36, Eliana Miranda, MD, PhD37, David Richardson38, Zainab Mohamed39, Estelle Verburgh, MD, PhD40, Thomas Eipe, PharmD41, Tanuja Shet42, Hasmukh Jain, MD43, Manju Sengar, MD,DM44, Cesar Samanez-Figari, MD45, Melvy Guerrero46, Marcus Watkins, PhD47, Neha Mehta-Shah, MD, MSCI48, Carrie van der Weyden, MD49, Jule Franve Vasquez, MD50, Carlos Barrionuevo, MD51, Daniela Duenas52, Johanna Rojas, MD53, David Garrido, MD54, Andrés Garcés Arias, MD55, Kusha Chopra, BS56, Caroline T MacVicar, BS57, Anna Rider58, Corben Yuwai Wong, BS59, Emma DeMarco, BS60, Riya Bhattacharjee, BS61, Xuan Cheng, BS62, Catherine Cho63, Valentina Nardi, MD64, Jeffrey Barnes, MD, PhD65, Teresa Palomero, PhD66, Robert Willim, MD67, Meredith Nichols, MD68, Esther Rheinbay, PhD69, Enrica Marchi, MD, PhD70, Stefan K Barta, MD71, Tatyana Feldman, MD72, Christina Poh, MD73, Basem William, MD, MRCP(UK), FACP74, Nathan Lee Roberts, MD75, Danielle Blunt, BMBS76, Takashi Sakamoto, MD, PhD77, Yumeng Zhang, MD78, Bradley Haverkos, MD79, Mitsumasa Watanabe, MD80, Nora Bennani, MD81, Yun Kyoung Tiger, MD, PhD82, Jonathan Brammer, MD83, Pamela Allen, MD84, Deepa Jagadeesh, MD, MPH85, Mark Sloan, MD86, Maya deepti Srinivasan, MD, MSc87, Lauren Shea, MD88, Harsh Rohit Shah, DO89, Sonali Smith, MD, FASCO90, Nazila Shafagati, M.D.91, Bhagirathbhai Dholaria, MD, FACP92, Raul Rabadan, MD93, Salvia Jain94
1 Columbia University, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
3 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
4 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
5 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
6 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
7 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
8 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
9 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
10 Dana Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
13 Instituto de Cancerología de Guatemala (INCAN), Ciudad de Guatemala, Guatemala
14 Yonsei University College of Medicine, Seoul, Korea, Rep. of South
15 Yonsei University College of Medicine, Seoul, Korea, Rep. of South
16 Hospital Edgardo Rebagliati, Lima, Peru, Universidad Ricardo Palma, Lima, Peru
17 Hospital Edgardo Rebagliati, Lima, Peru, Universidad Ricardo Palma, Lima, Peru
18 Hospital Edgardo Rebagliati, Lima, Peru, Universidad Ricardo Palma, Lima, Peru
19 Hospital Edgardo Rebagliati, Lima, Peru, Universidad Ricardo Palma, Lima, Peru
20 MD Anderson Cancer Center, Houston, Houston, Texas, United States
21 MD Anderson Cancer Center, Houston, Houston, Texas, United States
22 University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
23 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
24 Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain
25 Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain
26 Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain
27 Weill Cornell Medicine, New York City, New York, United States
28 Weill Cornell Medicine, New York City, New York, United States
29 Hospital del Salvador, Santiago, Chile
30 Hospital del Salvador, Santiago, Chile
31 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Rep. of South
32 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Rep. of South
33 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Rep. of South
34 Saint Louis University School of Medicine, SSM Health, St. Louis, Missouri, United States
35 Columbia University Irving Medical Center, New York City, New York, United States
36 Facultad de Ciencias Médicas de Santa Casa de São Paulo, São Paulo, Brazil
37 Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
38 Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
39 Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
40 Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
41 Tata Memorial Hospital, Mumbai, India
42 Tata Memorial Hospital, Mumbai, India
43 Tata Memorial Hospital, Mumbai, India
44 Tata Memorial Hospital, Mumbai, India
45 Oncosalud, AUNA, Lima, Peru
46 Oncosalud, AUNA, Lima, Peru
47 Washington University in St. Louis, St. Louis, Missouri, United States
48 Washington University in St. Louis, St. Louis, Missouri, United States
49 Peter MacCallum Cancer Center, Melbourne, Australia
50 Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
51 Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
52 MD Anderson Cancer Center, Houston, Houston, Texas, United States
53 Hospital Metropolitano, Quito, Ecuador
54 Hospital Metropolitano, Quito, Ecuador
55 Hospital Alma Mater, Universidad de Antioquia, Medellin, Colombia
56 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
57 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
58 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
59 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
60 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
61 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
62 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
63 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
64 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
65 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
66 Columbia University Irving Medical Center, New York City, New York, United States
67 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
68 Cleveland Clinic, Cleveland, Ohio, United States
69 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
70 Dana Farber Cancer Institute, Boston, Massachusetts, United States
71 University of Pennsylvania, Philadelphia, Pennsylvania, United States
72 Hackensack Meridian Health Network, Hackensack, New Jersey, United States
73 City of Hope, Los Angeles, California, United States
74 OhioHealth, Columbus, Ohio, United States
75 University of Virginia Cancer Center, Charlottesville, Virginia, United States
76 Royal Adelaide Hospital, Adelaide, Australia
77 Kyoto University Hospital, Kyoto, Japan
78 Moffitt Cancer Center, Tampa, Florida, United States
79 University of Colorado, Denver, Colorado, United States
80 Amagasaki General Medical Center, Amagasaki, Japan
81 Mayo Clinic, Rochester, Minnesota, United States
82 Mayo Clinic, Rochester, Minnesota, United States
83 Ohio State University Wexner Medical Center, Columbus, Ohio, United States
84 Emory University, Atlanta, Georgia, United States
85 Cleveland Clinic, Cleveland, Ohio, United States
86 Boston Medical Center, Boston, Massachusetts, United States
87 Boston Medical Center, Boston, Massachusetts, United States
88 University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States
89 Huntsman Cancer Institute, Salt Lake City, Utah, United States
90 University of Chicago, Chicago, Illinois, United States
91 University of Chicago, Chicago, Illinois, United States
92 Vanderbilt University Medical Center, Nashville, Tennessee, United States
93 Columbia University, New York, New York, United States
94 Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

INTRODUCTION

Advanced ENKTCL is an aggressive EBV-associated neoplasm with poor outcomes and no established genomic or biomarker-driven therapy. We conducted a global multiomic study integrating tumor genomic, transcriptomic, viral, and germline profiling to identify actionable vulnerabilities for a candidate therapeutic strategy.

METHODS

We profiled 133 FFPE ENKTCL tumors across 20 institutions/12 countries by WES (n=125), WGS and bulk RNA-seq(n=115), through collaboration among PETAL, GELL consortia and others. We assessed HLA class I loss of heterozygosity (LOH) and allele-specific expression (ASE) loss, validated in an independent, previously published Chinese cohort, and reconstructed a phylogeny of 244 EBV genomes, including 107 newly sequenced from this cohort. Golidocitinib, a JAK1 inhibitor, was tested in five ENKTCL lines (KHYG-1, NK-92, NK-YS, SNK6, YT) and in IL-78 PDx and NK-YS cell line xenografts randomized to vehicle, golidocitinib, anti–PD-1, or combination (n=5/group).

RESULTS

The cohort comprised primary (n=130) and relapsed tumors (n=3) from patients with admixed genetic ancestry spanning East Asian, European, Indigenous American, African, and South Asian components. Driver mutations were present in 100/125 cases (80%), most frequently KMT2D (20%), BCOR (13%), DDX3X (11%), and ARID1A, MSN, and TP53 (10% each). JAK–STAT genes were mutated in 38%: including STAT3 (18%), JAK3 (10%), STAT5B (7%), and JAK1 and SOCS1 (6% each). Copy-number analysis (n=115) identified gains at 17q21.2 (STAT3/STAT5B; 44%) and 9p24.1 (PD-L1; 29%), which co-occurred more often than expected (OR 10.9, q<0.001). Overall, 71/115 cases (62%) harbored a JAK–STAT mutation and/or 17q21.2 or 9p24.1 gain.

PD-L1 (CD274) protein expression correlated with JAK–STAT gene mutations, most strongly with STAT3. STAT3-mutant tumors (n=21) showed higher immune-checkpoint (p=0.021) and JAK–STAT signature expression (p=0.045) than wild-type tumors (n=79); no other JAK-STAT mutation showed this association.

ASE loss occurred in 109/115 (95%) cases, substantially exceeding LOH (32/122, 26%) and the highest ASE loss rate reported across TCGA tumor types (86%), and was replicated in the independent Chinese cohort (97%). ASE loss was allele-selective: A*02:01, an allele linked to reduced risk of EBV-positive Hodgkin lymphoma, was lost in 39/45 (87%, q <0.001) cases, whereas A*11:01, prevalent in Asian and South American populations, was lost in 3/31 (10%, q <0.001) cases. Germline HLA-A*02 supertype carriage was less frequent in STAT3-mutant than wild-type cases (27% [n=11] vs 74% [n=61]; p=0.0047).

Phylogeny of 244 EBV genomes from EBV-associated conditions identified 12 groups structured by viral type (R2=0.38) and population origin (R2=0.28; both p<0.001). ENKTCL strains spanned 10/12 groups alongside strains from other conditions, and their apparent disease association (p=0.003) disappeared after adjusting for population origin (p=0.88).

In vitro, golidocitinib was cytotoxic across all 5 cell lines (2.2–4.2-fold over DMSO), reduced phosphorylation of STAT1, STAT3, STAT5, AKT, and ERK, induced G0/G1 arrest (NK-92, 67.8%–86.9%; SNK6, 68.4%–92.5%), reduced proliferation by 72%–81%, increased XCL1 (p<0.05), and decreased IL-10 levels (p=0.053). In the IL-78 PDX model, circulating hCD3+ burden was reduced from a mean of 8% to 2% with golidocitinib or combination at week 1 (both p<0.0001) and through week 3 (both p<0.05), including endpoint marrow involvement (mean 4.5% vs 1.5%; both p<0.05). In the NK-YS model, golidocitinib and the combination suppressed growth at week 6 (p=0.001 and p=0.003) and at week 8 endpoint (p=0.003 and p=0.001).

CONCLUSIONS

In this global ENKTCL cohort, JAK–STAT mutations and 17q21.2/9p24.1 gains converged in two thirds of tumors, with STAT3-mutant tumors showing increased JAK–STAT and immune-checkpoint expression. HLA-I immune evasion occurred predominantly through ASE loss rather than LOH and was independently replicated. EBV genomic structure reflected viral type and patient geographic origin, rather than disease association. Golidocitinib showed broad in vitro cytotoxicity and suppressed JAK–STAT signaling irrespective of STAT3 or JAK1 mutation status, reduced tumor growth in vivo, alone and in combination with PD-1 blockade. These findings support early-phase evaluation of golidocitinib with PD-1 blockade in ENKTCL with prospective assessment of STAT3 mutation and PD-L1 gain and/or expression as candidate enrichment biomarkers.

Maria J. Fernandez-Turizo, MD: No relevant conflicts of interest to declare.